Vemurafenib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3191 publications

Targeted Therapy in Erdheim-Chester Disease: A Case Report and Review of the Literature.

Targeted Therapy in Erdheim-Chester Disease: A Case Report and Review of the Literature.

Journal: Cureus
Published: May 22, 2026

Clinical Features, Diagnosis and Prognosis of Vemurafenib-Induced Uveitis.

Clinical Features, Diagnosis and Prognosis of Vemurafenib-Induced Uveitis.

Journal: Seminars in ophthalmology
Published: May 06, 2026

Primary ovarian malignant melanoma: A systematic review of cases and pooled analysis.

Primary ovarian malignant melanoma: A systematic review of cases and pooled analysis.

Journal: Gynecologic oncology
Published: April 20, 2026

Inhibitory effect of vemurafenib combined with panobinostat on human anaplastic thyroid cancer cells.

Inhibitory effect of vemurafenib combined with panobinostat on human anaplastic thyroid cancer cells.

Journal: Pakistan journal of pharmaceutical sciences
Published: March 25, 2026

Corrigendum to 'The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma': [Journal of Investigative Dermatology, Volume 135, Issue 5, May 2015, Pages 1368-1376].

Corrigendum to 'The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma': [Journal of Investigative Dermatology, Volume 135, Issue 5, May 2015, Pages 1368-1376].

Journal: The Journal of investigative dermatology
Published: March 13, 2026

Development and Preliminary Evaluations of a Novel 18F-Labeled Tracer for Detection of BRAFV600E Mutant Status in Animal Models of Melanoma.

Development and Preliminary Evaluations of a Novel 18F-Labeled Tracer for Detection of BRAFV600E Mutant Status in Animal Models of Melanoma.

Journal: Molecular pharmaceutics
Published: March 13, 2026

Uveitis Associated with Protein Kinase Inhibitors in Cancer Patients: A Risk-Based Ophthalmologic Management.

Uveitis Associated with Protein Kinase Inhibitors in Cancer Patients: A Risk-Based Ophthalmologic Management.

Journal: Ocular immunology and inflammation
Published: March 13, 2026

Benzimidazole derivatives as dual EGFR and BRAFV600E inhibitors with pro-apoptotic antiproliferative potential.

Benzimidazole derivatives as dual EGFR and BRAFV600E inhibitors with pro-apoptotic antiproliferative potential.

Journal: RSC advances
Published: March 12, 2026

Erlotinib and Leflunomide Disrupt 6-Formylindolo[3,2-b]Carbazole Metabolism and Sensitize Keratinocytes to UVA Radiation-Induced Apoptosis.

Erlotinib and Leflunomide Disrupt 6-Formylindolo[3,2-b]Carbazole Metabolism and Sensitize Keratinocytes to UVA Radiation-Induced Apoptosis.

Journal: Photodermatology, photoimmunology & photomedicine
Published: February 26, 2026

Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells.

Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells.

Journal: Journal of proteome research
Published: February 25, 2026

Rebound regrowth phenomenon in patients with pediatric low-grade gliomas treated with MAPK inhibitors - a systematic review.

Rebound regrowth phenomenon in patients with pediatric low-grade gliomas treated with MAPK inhibitors - a systematic review.

Journal: Oncology reviews
Published: February 23, 2026

Multiple opportunistic infections revealing Erdheim-Chester disease: an atypical presentation.

Multiple opportunistic infections revealing Erdheim-Chester disease: an atypical presentation.

Journal: BMJ case reports
Published: February 19, 2026
Showing 1-12 of 3,191

Last Updated: 06/30/2026